Nevertheless, the response rate of MS patients to IFN-β treatment is average, and within two years of the initial injection of IFN-β, nearly 40–50% of patients suffer from the first relapse [4], indicating poor or no response at all to the IFN-β treatments. Here, IFNB1 is linked to myeloid sarcoma.